Kodiak Sciences (NASDAQ:KOD) Shares Gap Down - Time to Sell?

Key Points

• Kodiak Sciences shares gapped down from a prior close of $39.98 to $37.40, though they later traded at $40.11. The stock has a $2.55 billion market capitalization and trades above its 50-day and 200-day moving averages.
• Analyst sentiment is generally positive: six analysts rate the stock Buy, one rates it Hold and one rates it Sell. The consensus rating is “Moderate Buy,” with an average price target of $48.14, including targets as high as $66.
• The company reported a quarterly loss of $1.05 per share, missing the $0.96 consensus estimate, and analysts expect a full-year loss of $3.74 per share. Kodiak is a clinical-stage biotech developing retinal-disease treatments, led by its KSI-301 anti-VEGF candidate.

Shares of Kodiak Sciences Inc. (NASDAQ:KOD - Get Free Report) gapped down before the market opened on Friday . The stock had previously closed at $39.98, but opened at $37.40. Kodiak Sciences shares last traded at $40.11, with a volume of 106,303 shares trading hands.

Analyst Ratings Changes

KOD has been the topic of a number of research analyst reports. Chardan Capital raised Kodiak Sciences from a "neutral" rating to a "buy" rating and lifted their target price for the stock from $14.00 to $61.00 in a report on Monday, May 11th. JPMorgan Chase & Co. raised their price objective on shares of Kodiak Sciences from $56.00 to $66.00 and gave the company an "overweight" rating in a research report on Monday, August 3rd. Wall Street Zen raised shares of Kodiak Sciences from a "sell" rating to a "hold" rating in a research note on Saturday, May 16th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Kodiak Sciences in a report on Friday, July 10th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $48.14.

Kodiak Sciences Trading Up 1.8%

The stock has a 50-day moving average of $38.90 and a two-hundred day moving average of $34.90. The firm has a market cap of $2.55 billion, a price-to-earnings ratio of -9.79 and a beta of 2.21.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.96) by ($0.09). Sell-side analysts expect that Kodiak Sciences Inc. will post -3.74 EPS for the current fiscal year.

Institutional Investors Weigh In On Kodiak Sciences

A number of large investors have recently made changes to their positions in the company. AQR Capital Management LLC acquired a new position in Kodiak Sciences in the 1st quarter worth approximately $188,000. Dynamic Technology Lab Private Ltd acquired a new stake in Kodiak Sciences during the 1st quarter valued at $94,000. Jane Street Group LLC raised its stake in Kodiak Sciences by 441.3% during the 1st quarter. Jane Street Group LLC now owns 64,649 shares of the company's stock valued at $181,000 after purchasing an additional 52,705 shares during the period. American Century Companies Inc. lifted its holdings in shares of Kodiak Sciences by 6.3% in the second quarter. American Century Companies Inc. now owns 79,745 shares of the company's stock valued at $297,000 after purchasing an additional 4,703 shares in the last quarter. Finally, Federated Hermes Inc. lifted its holdings in shares of Kodiak Sciences by 190.7% in the second quarter. Federated Hermes Inc. now owns 244,231 shares of the company's stock valued at $911,000 after purchasing an additional 160,225 shares in the last quarter. Institutional investors and hedge funds own 89.06% of the company's stock.

About Kodiak Sciences

Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company's proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak's research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak's pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source